FindTrial
Sign In

Platinum Doublet

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Regeneron Pharmaceuticals, Montefiore Medical Center, Sun Yat-sen University

Conditions

Autoimmune DiseaseCrohn DiseaseDermatomyositisHead and Neck Squamous Cell CarcinomaHematopoietic and Lymphoid Cell NeoplasmHepatocellular CarcinomaInflammatory Bowel DiseaseMalignant Solid Neoplasm

Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingNCT03816345
National Cancer Institute (NCI)Autoimmune Disease, Crohn Disease, Dermatomyositis +11
Start: 2019-07-16End: 2028-03-30Target: 300Updated: 2026-05-13

Phase 2

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Active, not recruitingNCT03916627
Regeneron PharmaceuticalsHead and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Start: 2019-07-23End: 2030-05-14Updated: 2026-04-06
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Active, not recruitingNCT05500092
Montefiore Medical CenterResectable Stage IIA to IIIB Non-small Cell Lung Cancer
Start: 2023-01-25End: 2030-05-01Updated: 2026-01-28
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
RecruitingNCT06977074
Sun Yat-sen UniversityNon-small Cell Lung Cancer (NSCLC)
Start: 2025-05-10End: 2030-05-10Target: 83Updated: 2025-05-23

Related Papers

Abstract C063: <i>Bacteroidetes</i> Enrichment Associated with Immune Checkpoint Blockade Resistance and Promotes Tumorigenesis in Hepatocellular Carcinoma
Cancer Immunology Research2026-02-18
Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Journal of Clinical Oncology2025-05-28
LBA4 Low-dose stereotactic body radiotherapy prior to pre-operative cemiplimab for patients with resectable hepatocellular carcinoma
Immuno-Oncology Technology2023-12-01
Abstract 2178: Circulating tumor DNA (ctDNA) correlates closely with tumor necrosis and relapse-free survival (RFS) in hepatocellular carcinoma (HCC) patients treated with perioperative cemiplimab
Cancer Research2023-04-043 citations
541 mregDC/T helper niches enable local reactivation of CD8 T cells upon PD-1 blockade
Regular and Young Investigator Award Abstracts2022-11-012 citations
690 Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression
Regular and Young Investigator Award Abstracts2022-11-01
688 Prediction of HCC response to neoadjuvant immunotherapy using multiparametric magnetic resonance imaging: a preliminary study
Regular and Young Investigator Award Abstracts2022-11-01
543 Response to checkpoint blockade in HCC is associated with IgG1 skewing
Regular and Young Investigator Award Abstracts2022-11-01
576 Comprehensive single cell sequencing analysis of paired tissue and blood samples from HCC patients treated with neoadjuvant anti-PD-1 therapy reveals treatment-induced clonal T cell dynamics
Regular and Young Investigator Award Abstracts2022-11-01
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
2022-01-20173 citations
361 Heterogeneity of PD-1hi T cells associates with response to PD-1 blockade in hepatocellular carcinoma
Regular and Young Investigator Award Abstracts2021-11-01
685 Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma
Regular and Young Investigator Award Abstracts2021-11-01
Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma
Cancer Research2021-07-014 citations
Abstract 64: Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma
Cancer Research2021-07-011 citations
Abstract 515: Heterogeneity of PD-1hi CD8 T cells associates with response to PD-1 blockade in hepatocellular carcinoma
Cancer Research2021-07-01
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
2021-06-2334 citations
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Journal of Clinical Oncology2021-05-2029 citations
[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
2021-04-015 citations
Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)
Cancer Research2020-08-15
A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Journal of Clinical Oncology2020-05-206 citations